Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG.
The addition of the gonadotropin releasing hormone (GnRH) agonist Buserelin to human menopausal gonadotrophin/human chorionic gonadotropin (HMG/HCG) during ovarian stimulation was evaluated in 23 cycles of 21 women who previously had unsuccessful IVF treatments when stimulated with clomiphene--HMG/HCG. No adverse effects of GnRH-agonist on folliculogenesis were seen. A mean number of 7.2 oocytes per retrieval was collected in 20 treatment cycles. Oocytes quality, fertilization and cleavage parameters were normal. Replacements by gamete intra-Fallopian transfer (GIFT) or IVF took place for 16 patients. Four patients became pregnant in their treatment cycle, one aborted. For 8 patients 18 embryos were cryopreserved, one transfer of a frozen--thawed embryo in a subsequent natural cycle led to a pregnancy. Inadequate luteal phases were constantly observed when supplementation was omitted. Further study is required to confirm that systematic luteal support improves the pregnancy rate.
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D006063:Chorionic Gonadotropin / Q000097:blood; D004338:Drug Combinations; D004958:Estradiol / Q000097:blood; D005187:Fallopian Tubes; D005260:Female; D005307:Fertilization in Vitro; D005615:Freezing; D006801:Humans; D008183:Luteal Phase; D008596:Menotropins / Q000627:therapeutic use*; D009865:Oocytes / Q000637:transplantation*; D010053:Ovary / Q000187:drug effects; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D014184:Transplantation, Homologous
D006063:Chorionic Gonadotropin; D004338:Drug Combinations; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D002064:Buserelin